{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:14:41Z","timestamp":1759058081816,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Turkish Scientific Research Council","award":["TUBITAK-106S223","109S353"],"award-info":[{"award-number":["TUBITAK-106S223","109S353"]}]},{"name":"AFM-Telethon","award":["#21125"],"award-info":[{"award-number":["#21125"]}]},{"DOI":"10.13039\/501100002657","name":"Istanbul University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002657","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jneuroim.2020.577402","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T02:05:59Z","timestamp":1600653959000},"page":"577402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients"],"prefix":"10.1016","volume":"349","author":[{"given":"V.","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tuzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Durmus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Oflazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Aysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Parman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gungor-Tuncer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Deymeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Saruhan-Direskeneli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jneuroim.2020.577402_bb0005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0020","first-page":"5","article-title":"Saas, Toussirot E4 on behalf of CBT-506. Peripheral blood B cell subsets and BAFF\/APRIL levels and their receptors are disturbed in rheumatoid arthritis but not in ankylosing spondylitis","volume":"4","author":"Gaugler","year":"2013","journal-title":"Clin. Cell. Immunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2020.577402_bb0025","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577402_bb0035","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-cell-activating factor is elevated in serum of patients with myasthenia gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2020.577402_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis","volume":"199","author":"Kim","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2020.577402_bb0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2020.577402_bb0060","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2014.12.006","article-title":"An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis","volume":"52","author":"Motobayashi","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0065","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.pediatrneurol.2016.06.013","article-title":"Usefulness of circulating B-celleactivating factor serial monitoring in childhood-onset ocular myasthenia gravis","volume":"63","author":"Motobayashi","year":"2016","journal-title":"Pediatr. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2020.577402_bb0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.5966\/sctm.2014-0001","article-title":"Alteration of na\u00efve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells","volume":"3","author":"Peng","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0075","article-title":"B-cell-activating factor and autoimmune myasthenia gravis","volume":"2011","author":"Ragheb","year":"2011","journal-title":"Autoimmune Dis."},{"issue":"10","key":"10.1016\/j.jneuroim.2020.577402_bb0080","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"BSA potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577402_bb0090","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1007\/s00415-011-6092-z","article-title":"BAFF serum levels in myasthenia gravis: effects of therapy","volume":"258","author":"Scuderi","year":"2011","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2020.577402_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2020.577402_bb0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.05.023","article-title":"The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis","volume":"178","author":"Thangarajh","year":"2006","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577402_bb0105","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/intimm\/8.6.815","article-title":"Co-ligation of surface IgM and CD40 on naive B lymphocytes generates a blast population with an ambiguous extrafollicular\/germinal center cell phenotype","volume":"8","author":"Wheeler","year":"1996","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2020.577402_bb0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/08916934.2014.992517","article-title":"B cells produce less IL-10, IL-6 and TNF-\u03b1 in myasthenia gravis","volume":"48","author":"Yilmaz","year":"2015","journal-title":"Autoimmunity"},{"issue":"11","key":"10.1016\/j.jneuroim.2020.577402_bb0115","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/acn3.645","article-title":"Regulatory B cells in myasthenia gravis are differentially affected by therapies","volume":"5","author":"Yilmaz","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820302204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820302204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:36:42Z","timestamp":1759048602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820302204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"alternative-id":["S0165572820302204"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577402","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577402"}}